Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 5,280 Shares of Stock

March 20, 2026 by InsiderTrades.com

Key Points

CEO Jack Bendheim sold 5,280 shares on March 17 at $51.66 (≈$272,765), part of a broader wave of insider sales—including a 58,014‑share sale on Feb. 10 (~$3.01M)—that reduced his stake by 5.49% to 90,920 shares.
Phibro carries a $2.12B market cap, recently beat quarterly expectations (EPS $0.87 vs. $0.69; revenue $373.9M vs. $355.6M), provided FY2026 EPS guidance of $2.93–3.10, and announced a quarterly dividend of $0.12 (0.9% yield).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 5,280 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $51.66, for a total value of $272,764.80. Following the completion of the transaction, the chief executive officer owned 90,920 shares of the company's stock, valued at $4,696,927.20. The trade was a 5.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jack Bendheim also recently made the following trade(s):

On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.52, for a total value of $369,740.80.
On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.68, for a total transaction of $556,300.80.
On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80.
On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20.
On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total transaction of $361,644.80.
On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total transaction of $361,996.80.
On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00.
On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.
On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.62, for a total transaction of $732,178.08.
On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.

Phibro Animal Health Stock Up 0.3%

NASDAQ PAHC opened at $52.38 on Friday. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $56.30. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 23.28, a PEG ratio of 0.80 and a beta of 0.74. The stock's 50 day moving average is $47.34 and its two-hundred day moving average is $42.65. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analysts' expectations of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health's dividend payout ratio is currently 21.33%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Caitlin John LLC acquired a new position in shares of Phibro Animal Health during the fourth quarter valued at $266,000. Mackenzie Financial Corp increased its position in Phibro Animal Health by 7.1% in the fourth quarter. Mackenzie Financial Corp now owns 50,619 shares of the company's stock worth $1,895,000 after purchasing an additional 3,355 shares during the period. XTX Topco Ltd raised its holdings in Phibro Animal Health by 125.4% during the 4th quarter. XTX Topco Ltd now owns 16,233 shares of the company's stock worth $606,000 after purchasing an additional 9,032 shares during the last quarter. Zacks Investment Management raised its holdings in Phibro Animal Health by 13.2% during the 4th quarter. Zacks Investment Management now owns 91,391 shares of the company's stock worth $3,414,000 after purchasing an additional 10,642 shares during the last quarter. Finally, VARCOV Co. acquired a new position in Phibro Animal Health during the 4th quarter valued at about $672,000. Institutional investors own 99.34% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research note on Friday, February 6th. Zacks Research raised shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. Finally, Weiss Ratings restated a "buy (b-)" rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.50.

View Our Latest Report on PAHC

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.